论文部分内容阅读
目的探讨血清血管内皮生长因子(serum vascular endothelial growth factor,sVEGF)水平在小细胞肺癌(SCLC)诊治中的临床价值。方法用放射免疫的方法检测69例未经任何治疗的SCLC患者sVEGF水平以及治疗后的sVEGF水平,同时用相同方法检测了50例健康体检者的sVEGF水平作为对照,分析SCLC患者与健康体检者的sVEGF水平差异,并分析SCLC患者sVEGF水平与临床分期及治疗效果之间的关系。结果 SCLC组sVEGF水平[(236.83±72.35)ng/ml]明显高于健康对照组[(114.18±27.57)ng/ml,t=12.853,P<0.001],广泛期患者的sVEGF浓度[(263.09±81.30)ng/ml]高于局限期浓度[(204.63±42.04)ng/ml,t=-3.846,P<0.001],治疗有效组治疗后sVEGF水平[(129.43±29.12)ng/ml]低于治疗前[(236.90±68.76)ng/ml,P<0.05],治疗无效组治疗后sVEGF水平[(236.72±78.60)ng/ml]与治疗前[(258.70±72.93)ng/ml,t=-1.100,P=0.281]无明显变化。结论 sVEGF浓度检测有助于SCLC诊断,监测治疗前后SCLC患者sVEGF浓度变化对评价治疗效果具有积极的意义。
Objective To investigate the clinical value of serum vascular endothelial growth factor (sVEGF) in the diagnosis and treatment of small cell lung cancer (SCLC). Methods Radioimmunoassay was used to detect the sVEGF level in 69 patients with SCLC without any treatment and the sVEGF level after treatment. The sVEGF levels in 50 healthy subjects were detected by the same method. The levels of sVEGF in SCLC patients and healthy controls sVEGF levels, and analyze the relationship between SCV patients sVEGF levels and clinical stage and treatment effect. Results The level of sVEGF in SCLC group was significantly higher than that in healthy control group [(236.83 ± 72.35) ng / ml [(114.18 ± 27.57) ng / ml, t = 12.853, (129.33 ± 29.12) ng / ml] was lower than that of the control group [(81.30) ng / ml] [(204.63 ± 42.04) ng / ml, t = -3.846, The levels of sVEGF in the treatment - ineffective group [(236.72 ± 78.60) ng / ml] and before treatment [(258.70 ± 72.93) ng / ml, t = - 1.100, P = 0.281] no significant change. Conclusion The detection of sVEGF concentration is helpful for the diagnosis of SCLC. It is of great significance to evaluate the therapeutic effect of sVEGF in SCLC patients before and after treatment.